Dr. Arkenau on the Potential of Immunotherapy in Gastric Cancer

Hendrik-Tobias Arkenau, MD, PhD
Published: Wednesday, Dec 05, 2018



Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Cannon Research Institute UK, discusses the potential of immunotherapy in gastric cancer.

Immunotherapy has shown benefit in some patients with gastric cancer, and 2 agents are currently approved in the third-line setting—nivolumab (Opdivo) and pembrolizumab (Keytruda). However, not all patients benefit, so biomarkers such as PD-L1 are used for proper patient selection. Although it has been shown that patients with higher PD-L1 have better outcomes, Arkenau says there are many patients who are PD-L1–negative who derive benefit from immunotherapy.

In gastrointestinal cancer, tumor mutational burden and microsatellite instability (MSI) are often looked to in addition to PD-L1 as predictors of response to immunotherapy. The approval of pembrolizumab in gastric cancer came from a study of patients with MSI-high tumors. Considering studies like these, as well as what has been seen with PD-L1, Arkenau says that the field needs to focus on biosimilar optimization in order to use immunotherapy effectively.
SELECTED
LANGUAGE


Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Cannon Research Institute UK, discusses the potential of immunotherapy in gastric cancer.

Immunotherapy has shown benefit in some patients with gastric cancer, and 2 agents are currently approved in the third-line setting—nivolumab (Opdivo) and pembrolizumab (Keytruda). However, not all patients benefit, so biomarkers such as PD-L1 are used for proper patient selection. Although it has been shown that patients with higher PD-L1 have better outcomes, Arkenau says there are many patients who are PD-L1–negative who derive benefit from immunotherapy.

In gastrointestinal cancer, tumor mutational burden and microsatellite instability (MSI) are often looked to in addition to PD-L1 as predictors of response to immunotherapy. The approval of pembrolizumab in gastric cancer came from a study of patients with MSI-high tumors. Considering studies like these, as well as what has been seen with PD-L1, Arkenau says that the field needs to focus on biosimilar optimization in order to use immunotherapy effectively.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x